{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-25-000035","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.969272+00:00","generated_at":"2026-05-26T02:24:10.321894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M","bullets":["Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).","Full year 2024 revenue $792.3M, net income $16.4M (2.1% margin), Adjusted EBITDA $260.2M (32.8% margin).","Q4 operating cash flow $44.7M, full-year $183.9M; over 7 million prescription consumers at quarter end.","Results described as substantially in-line with previous guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-25-000035","json":"https://secwatch.observer/filing/0001809519-25-000035.json","markdown":"https://secwatch.observer/filing/0001809519-25-000035.md","text":"https://secwatch.observer/filing/0001809519-25-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/0001809519-25-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/gdrx-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:24:10.321894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}